These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 15872030)

  • 1. Perindopril in diabetes: perspective from the EUROPA substudy, PERSUADE.
    Verma S; Leiter LA; Lonn EM; Strauss MH
    Eur Heart J; 2005 Jul; 26(14):1347-9. PubMed ID: 15872030
    [No Abstract]   [Full Text] [Related]  

  • 2. The effect of perindopril on cardiovascular morbidity and mortality in patients with diabetes in the EUROPA study: results from the PERSUADE substudy.
    Daly CA; Fox KM; Remme WJ; Bertrand ME; Ferrari R; Simoons ML;
    Eur Heart J; 2005 Jul; 26(14):1369-78. PubMed ID: 15860521
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PERSUADE...(a EUROPA sub-study)...results: perindopril protects diabetic patients with coronary disease from cardiovascular death and heart attacks.
    Cardiovasc J S Afr; 2004; 15(3):146. PubMed ID: 15356914
    [No Abstract]   [Full Text] [Related]  

  • 4. Effects of perindopril on long-term clinical outcome of patients with coronary artery disease and preserved left ventricular function.
    Bertrand ME; Remme WJ; Fox KM; Ferrari R; Simoons ML;
    Int J Cardiol; 2007 Sep; 121(1):57-61. PubMed ID: 17270296
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Angiotensin-converting enzyme inhibition with perindopril in patients with prior myocardial infarction and/or revascularization: a subgroup analysis of the EUROPA trial.
    Bertrand ME; Fox KM; Remme WJ; Ferrari R; Simoons ML
    Arch Cardiovasc Dis; 2009 Feb; 102(2):89-96. PubMed ID: 19303575
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Perindopril protects diabetics with coronary disease from cardiovascular death and heart attacks.
    Cardiovasc J S Afr; 2004; 15(2):98. PubMed ID: 15148549
    [No Abstract]   [Full Text] [Related]  

  • 7. Clinical synergy of perindopril and calcium-channel blocker in the prevention of cardiac events and mortality in patients with coronary artery disease. Post hoc analysis of the EUROPA study.
    Bertrand ME; Ferrari R; Remme WJ; Simoons ML; Deckers JW; Fox KM;
    Am Heart J; 2010 May; 159(5):795-802. PubMed ID: 20435188
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The cardioprotective effects of the angiotensin-converting enzyme inhibitor perindopril in patients with stable coronary artery disease are not modified by mild to moderate renal insufficiency: insights from the EUROPA trial.
    Brugts JJ; Boersma E; Chonchol M; Deckers JW; Bertrand M; Remme WJ; Ferrari R; Fox K; Simoons ML;
    J Am Coll Cardiol; 2007 Nov; 50(22):2148-55. PubMed ID: 18036453
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Angiotensin-converting enzyme inhibitors in patients with preserved left ventricular function: from EUROPA to PREAMI].
    Ferrari R; Papa K; Bernocchi P; Gimbatti OJ; Golcea SS; Bettini A; Ceconi C
    Ital Heart J; 2005 Nov; 6 Suppl 7():24S-32S. PubMed ID: 16485514
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Should angiotensin-converting enzyme inhibitors be used in all patients with coronary artery disease or restricted to those with a history of myocardial infarction or myocardial revascularization?
    Danchin N
    Arch Cardiovasc Dis; 2009 Feb; 102(2):81-3. PubMed ID: 19303573
    [No Abstract]   [Full Text] [Related]  

  • 11. The consistency of the treatment effect of an ACE-inhibitor based treatment regimen in patients with vascular disease or high risk of vascular disease: a combined analysis of individual data of ADVANCE, EUROPA, and PROGRESS trials.
    Brugts JJ; Ninomiya T; Boersma E; Remme WJ; Bertrand M; Ferrari R; Fox K; MacMahon S; Chalmers J; Simoons ML
    Eur Heart J; 2009 Jun; 30(11):1385-94. PubMed ID: 19346520
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Genetic determinants of treatment benefit of the angiotensin-converting enzyme-inhibitor perindopril in patients with stable coronary artery disease.
    Brugts JJ; Isaacs A; Boersma E; van Duijn CM; Uitterlinden AG; Remme W; Bertrand M; Ninomiya T; Ceconi C; Chalmers J; MacMahon S; Fox K; Ferrari R; Witteman JC; Danser AH; Simoons ML; de Maat MP
    Eur Heart J; 2010 Aug; 31(15):1854-64. PubMed ID: 20538738
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Hypertension, heart failure, myocardial infarction, secondary prevention: the role of perindopril].
    Rapezzi C; Ciliberti P; Graziosi M; Riva L
    Ital Heart J; 2005 Nov; 6 Suppl 7():40S-47S. PubMed ID: 16485516
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment benefit by perindopril in patients with stable coronary artery disease at different levels of risk.
    Deckers JW; Goedhart DM; Boersma E; Briggs A; Bertrand M; Ferrari R; Remme WJ; Fox K; Simoons ML
    Eur Heart J; 2006 Apr; 27(7):796-801. PubMed ID: 16497685
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Insight into ACE inhibition in the prevention of cardiac events in stable coronary artery disease: the EUROPA trial.
    Ferrari R; Bertrand ME; Remme WJ; Simoons ML; Deckers JW; Fox KM
    Expert Rev Cardiovasc Ther; 2007 Nov; 5(6):1037-46. PubMed ID: 18035919
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Specific properties and effect of perindopril in controlling the renin-angiotensin system.
    Ferrari R; Pasanisi G; Notarstefano P; Campo G; Gardini E; Ceconi C
    Am J Hypertens; 2005 Sep; 18(9 Pt 2):142S-154S. PubMed ID: 16125051
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Do ACE inhibitors have a real role in coronary artery disease?
    Cardiovasc J S Afr; 2003; 14(3):156. PubMed ID: 12934579
    [No Abstract]   [Full Text] [Related]  

  • 18. Efficacy of perindopril in reducing risk of cardiac events in patients with revascularized coronary artery disease.
    Fox KM; Bertrand ME; Remme WJ; Ferrari R; Simoons ML; Deckers JW;
    Am Heart J; 2007 Apr; 153(4):629-35. PubMed ID: 17383303
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Scientific value of the EUROPA Study: mechanisms of beneficial effect of perindopril in atherosclerosis].
    Karpov IuA
    Kardiologiia; 2005; 45(2):86-9. PubMed ID: 15798719
    [No Abstract]   [Full Text] [Related]  

  • 20. [Clinical study of the month. The EUROPA study: cardiovascular protection with perindopril in patients with stable coronary heart disease].
    Scheen AJ; Legrand V
    Rev Med Liege; 2003 Nov; 58(11):713-6. PubMed ID: 14748202
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.